SHIRE PLC (NASDAQ:SHPG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02(c) ofForm 8-K. Except as described above and below, all other information in Shire’sForm 8-Kfiled on November 24, 2017 remains unchanged.
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers
On November 20, 2017, Shire announced that Thomas Dittrich (54) will join Shire as Chief Financial Officer (“CFO”) of Shire. Mr. Dittrich will receive an annual equity grant on May 1, 2018 under Shire’s Long Term Incentive Plan (“LTIP”), with a maximum face value of 357% of his annual base salary, subject to customary terms applicable to members of the Executive Committee. The award will comprise 50% Performance Share Units (PSUs) and will vest after three years subject to the Company’s 2018 performance conditions being satisfied, with no consideration payable. An additional two year post vesting holding period will also apply.
In addition, Mr. Dittrich will be granted a replacement equity award to compensate him for partial forfeiture of his 2016 LTIP award from his previous employment. The replacement equity award was granted on March 29, 2018, with a maximum face value of CHF 333,333. The award will comprise 50% PSUs and will vest after three years subject to the Company’s 2018 performance conditions being satisfied, with no consideration payable. No other replacement awards or payments will be made to Mr. Dittrich.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits. The following exhibit is filed herewith: |
99.1Press Release dated April 3, 2018
EXHIBIT INDEX
|
ExhibitNo. |
Description |
| 99.1 | Press Release dated April 3, 2018 |
Shire plc ExhibitEX-99.1 2 dp89171_ex9901.htm EXHBIT 99.1 Exhibit 99.1 Press Release www.shire.com Director/PDMR Shareholding April 3,…To view the full exhibit click here
About SHIRE PLC (NASDAQ:SHPG)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
